Clinical analysis of vulvar cancer
Keywords:
Cancer, Vulvar, Recurrence, Chemotherapy, Gynecological, MalignantAbstract
Background: The purpose of this study is to understand the incidence, related factors, and the prognosis factors in order to avoid risk, proper method of diagnosis and treatment and reduce complications and provide the basis.
Methods: 85 Vulvar cancer (VC) patients treated in our hospital from 2002.10 to 2012.10 were collected and analyzed by retrospective comparative methods. SPSS19.0 application software was used for the statistical analysis. The clinical data are analyzed by chi-square and F test statistic methods. P < 0.05 was a significant difference between the judgment standard.
Results: During 10 years, we treated 3391 cases of the primary malignant tumors including 85 VC cases; VC was 2.89% (85/3391). The age was between 24～88 years old, mean was 57.09±12.93 yrs. old, variable age of the VC had been juvenescence trend (F=6. 013，P=0.016＜0.05＝). The differences between the urban and rural residential area have some influence to the onset of VC. Rural patients are more than urban patients. By statistical analysis, region distribution in these two groups was remarkably different=4.16，P=0.045＜0.05, but the urban proportion of patients in different years has no difference（χ2=0.080, P=0.777）.
Conclusion: The number of cases increased progressively in young age. VC patients were more in rural area than urban. History of malignant tumor and obesity has the positive correlation with VC. High-risk groups should be alert to the possibility of VC. Preoperative diagnosis should be Colposcopic, biopsy in order to improve the accuracy of earlier diagnosis. Vulvar resects have an effect on the healing of the incision. Follow-up rate is low; It is difficult to say statistically survival rate is 5 years.
Metrics
References
Mosher WD, Jones J. Use of contraception in the United States: 1982– 2008. Vital Health Stat 2010; 29:1-44.
Turkey demographic and health survey 2008, Hacettepe University Institute of Population Studies in collaboration with Turkish Republic Ministry of Health and Prime Ministry Undersecretary of State Planning Organization.
Mody SK, Kiley J, Rademaker A, et al. Pain control for intrauterine device insertion: a randomized trial of 1% lidocaine paracervical block. Contraception 2012;86:704-9.
Hubacher D, Reyes V, Lillo S, et al. Pain from copper intrauterine device insertion: randomized trial of prophylactic ibuprofen. Am J Obstet Gynecol 2006;195:1272-7.
Allen RH, Bartz D, Grimes DA, et al. Interventions for pain with intrauterine device insertion. Cochrane Database Syst Rev 2009;3:CD007373.
Dijkhuizen K, Dekkers OM, Holleboom CA, et al. Vaginal misoprostol prior to insertion of an intrauterine device: an RCT. Hum Reprod 2011; 26:323-9.
Edelman AB, Schaefer E, Olson A, et al. Effects of prophylactic misoprostol administration prior to intrauterine device insertion in nulliparous women. Contraception 2011;84:234-9.
Swenson C, Turok DK, Ward K, et al. Self-administered misoprostol or placebo before intrauterine device insertion in nulliparous women: a randomized controlled trial. Obstet Gynecol 2012; 120:341–7.
McNicholas CP, Madden T, Zhao Q, et al. Cervical lidocaine for IUD insertional pain: a randomized controlled trial. Am J Obstet Gynecol 2012;207: 384.e1-6.
Maguire K, Davis A, Rosario Tejeda L, Westhoff C. Intracervical lidocaine gel for intrauterine device insertion: a randomized controlled trial. Contraception 2012;86:214-9.
Chi IC, Wilkens LR, Champion CB, et al. Insertional pain and other IUD insertion-related rare events for breastfeeding and non-breastfeeding women-a decade's experience in developing countries. Adv Contracept 1989;5:101-19.
